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Why should an issue of CME, a publication 
primarily directed at generalists, be devoted 
to nuclear medicine? I am reminded from 
time to time of how unfamiliar many of my 
colleagues are with this specialty, which is not 
surprising given the minimal coverage the 
field receives in already full undergraduate 
medical school programmes – even 
specialty-specific postgraduate exposure 
is often limited. Consequently, there is a 
paucity of knowledge of the role, indications, 
availability, and cost of many nuclear 
medicine procedures in the wider clinical 
community. Optimal nuclear medicine is 
heavily reliant on close collaboration with 
referring clinicians. Two prerequisites for 
a clear, useful report is a clear definition of 
the clinical question and the study being 
appropriate to answer that question. It 
is primarily the responsibility of nuclear 
medicine physicians to advise colleagues 
on what studies can do and, sometimes 
more importantly, cannot do. However, if 
referring doctors have a good understanding 
of the role of nuclear medicine in their field, 
the contribution of the discipline to the 
management of their patients is likely to be 
enhanced. This issue of CME is therefore 
intended to inform and update the wider 
medical community about some of the more 
important studies and procedures available.
It has been 20 years since an issue of CME 
focused on nuclear medicine. In the issue 
of October 1993, titled ‘Imaging for the 
non-radiologist’, several articles covered 
subject matter that remains relevant in 
South Africa today. In the current issue 
several articles focus on established areas. 
These include an article on functional brain 
imaging, and articles on nuclear cardiology 
by Dr Carlos Libhaber, infection imaging 
by Professor Willy Vangu, and paediatric 
nuclear medicine by Dr Anita Brink. The 
content of this issue also reflects changes 
that have occurred over the last two 
decades. These include the convergence 
of functional and anatomical imaging, 
molecular imaging, targeted radiotherapy, 
and the increasing individualisation of 
patient management. In particular, a 
number of studies have entered routine use 
in oncology, of which the most important 
is positron emission tomography (PET), 
which was not available in South Africa 
20 years ago and is now well established 
in large centres. In their articles Professor 
Annare Ellmann, Dr Jen Holness, and Dr 
Tessa Kotze cover the most important areas 
of oncology in which nuclear medicine 
currently plays a role. The use of unsealed 
sources of radioactivity for targeted 
radiotherapy, another area which has 
undergone significant growth, is covered 
in an article by Professor Mike Sathekge.
An important development is the arrival of 
hybrid imaging systems. Previously, single 
photon emission computed tomography 
(SPECT) and PET scans were performed and 
mostly interpreted in isolation. Combined 
PET/CT and SPECT/CT scanners have 
become commonplace over the last 10 years. 
This development is significant, not only as a 
technological advance but more importantly 
because it is changing the way we work and 
think both within nuclear medicine and in 
our interaction with colleagues. Specifically, 
the interdependence of nuclear medicine 
and radiology resulting from hybridisation 
of functional and anatomical imaging is 
bringing the two disciplines into a more 
collaborative relationship, which ultimately 
benefits patients. In an article that Professor 
Jan Lotz and I co-authored, we have 
attempted to illustrate this interaction using 
a diverse selection of clinical situations.
Nuclear medicine is often associated with 
costly examinations, although this should 
not be true for the majority of studies. 
Further, while some studies are relatively 
costly to perform, if used appropriately 
they can reduce the overall cost of patient 
management, e.g. by avoiding futile surgery, 
ineffective chemotherapy, or more costly and 
invasive investigations, as well as sparing 
patients unnecessary side-effects. With 
the growing challenge of the escalating 
cost of healthcare and the National Health 
Insurance on the horizon in South Africa, the 
cost-effective utilisation of all disciplines, 
including nuclear medicine, is essential. It is 
hoped that this issue of CME will make some 
contribution towards that objective.
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F-18 Choline PET-CT scans
NTP Radioisotopes and AEC-Amersham proudly delivered, in July this year, the 
first in Africa commercial dose of F-18 Choline to Prof. Mike Sathekge, Head of the 
Departments of Nuclear Medicine at Steve Biko Academic Hospital and Pretoria 
University. The F-18 Choline radiopharmaceutical, used for accurate imaging and 
staging of prostate cancer, is synthesised in Necsa’s state-of-the-art clean room facility 
using the F-18 isotope produced by NTP. 
Tucked away on the slopes west of Pretoria at the Necsa nuclear 
facility is NTP Radioisotopes SOC Ltd, a company which has evolved into a 
seriously important global player in the radioactive business. Conducting its 
sophisticated operations amongst an array of state-of-the-art technology and 
highly competent scientists, engineers, technologists and radiopharmacists, 
NTP is one of the world’s leading suppliers of essential medical radioisotopes 
with strategic partners and associates ranking among the world’s leading 
pharmaceutical producers and their suppliers. 
A subsidiary of the South African Nuclear Energy Corporation (Necsa), NTP 
produces a range of radiochemicals, radiopharmaceuticals and industrial 
products that service the needs of domestic and international healthcare, life 
sciences and industrial markets – a market footprint covering 60 countries. 
Managing Director, Don Robertson, explains NTP has, over the past years, 
created various business subsidiaries or increased holdings, which strengthened 
its portfolio.  “Our growing company has facilities that are ISO9001:2008 
compliant and approved by all the world’s major medical regulatory 
bodies. The company is a world leader in the production and supply of 
radiochemicals and radiopharmaceuticals, in particular Iodine-131 (I-131) 
and Molybdenum-99 (Mo-99).  “The latter being the most important isotope for 
devices used in the practice of diagnostic nuclear medicine,” says Robertson. 
With a substantial track record of over 30 years of providing the South African 
medical community with radioisotope-based diagnostic imaging and therapy 
products, NTP and its wholly owned subsidiary AEC-Amersham supply a range 
of products used for millions of nuclear medical diagnostic scans and is also 
applied in treatments for conditions such as thyroid disease and lymphoma. 
Early detection of most diseases assisted by using nuclear medicine greatly 
enhances the possibility of early and accurate diagnosis.  This allows for prompt 
and proper treatment and, therefore, a better chance of a saved life!
NTP and AEC supply, amongst others, the following medical 
products: 
• I-131 for diagnosis and treatment of hyperthyroidism and 
thyroid cancer 
• Lu-177 n.c.a. labelled to DOTATATE for GEP-NET therapy 
• SirSpheres® Y-90 microspheres for selective internal 
radiation treatment for malignant liver cancer
• 18F-FDG for whole body PET-CT (Positron Emission 
Tomography – Computed Tomography) cancer imaging, 
staging, treatment planning and efficacy monitoring
• NaF-18 for high quality PET-CT imaging of bone 
metastases
• F-18 Choline for PET-CT imaging and accurate staging of 
prostate cancer
• I-131 MIBG for diagnosis and treatment of pheochromo-
cytoma
• Organ seeking “cold kits” for SPECT (Single Photon Emis-
sion Computed Tomography) imaging of the functionality 
of most organs of the body
• Generator for the Tc-99m isotope used in SPECT 
diagnostic imaging procedures
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South Africa’s First 18F-fluoride PET-CT Scan
